Breaking News


Azithromycin treatment of ocular symptoms in papulopustular rosacea patients


An open-label study of oral azithromycin 500 mg (3 consecutive days/week for 4 weeks) evaluated its efficacy on ocular symptoms in 20 patients (aged 26-79 years) with papulopustular rosacea. Significant improvement was seen in inflammatory lesion scores, eye symptom scores, eyelid finding scores, conjunctival hyperemia and the Schirmer 1 test (P < 0.001, P < 0.002, P < 0.0001, P < 0.005 and P = 0.012, respectively). No significant adverse events were seen (Bakar, O. et al. JEADV 2009, 23(5): 544).

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list